Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

P E Substitute for form 1449B/PTO		Complete if Known	
/ P TNEORMATION DISCLOSURE	Application Number	09/853,033	·
ATEMENT BY APPLICANT	Fifing Date	05/11/2001	
Date/Submitted: December 1, 2003	First Named Inventor	Pierre Chambon	
	Group Art Unit	1636	
(ase as many sheets as necessary)	Examiner Name	Celine X. Qian	
Sheet ADE 1 of 3	Attorney Docket Number	065691-0222	

	U.S. PATENT DOCUMENTS						
Examiner Initials*		U.S. Patent	Document	Al 45 4 4 4 4 4	Date of Publication of	Pages, Columns, Lines,	
		Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
CR.	A1	6,093,873	Α	CHAMBON et al.	07/25/2000		
				1			

-							
		4.	1				
							

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For Office ³	eign Patent D Number ⁴	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
CØ	A2	wo	95 00555	Α	EUROP MOLECULAR BIOLOGY LAB EM	01/05/1995	· igares / opear	Ť	
	A3	wo	94 26100	Α	INST NAT SANTE RECH	11/24/1994		\dagger	
	A4	WO	97 31108	Α	GRONEMEYER HINRICH	08/28/1997		+-	
	A5	WO	99 25851	A	SAITO IZUMU	05/27/1999		+	
	A6	WO	99 18222	Α	ALONSO JUAN C.	04/15/1999		1	
	A7	wo	92 06104	Α	DANA FARBER CANCER INST INC.	04/16/1992			
	A8	wo	00 49147	Α	THERAGENE BIOMEDICAL LAB GMBH	08/24/2000		\top	
	A9	wo	97 10819	Α	LIGAND PHARM INC.	03/27/1997		+	
V	A10	EP	0 698 392	A	OREAL	02/28/1996			

Examiner	 Date	1111-11
Signature	Considered	6111/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE 09/853,033 **Application Number** TATEMENT BY APPLICANT **Filing Date** 05/11/2001 First Named Inventor Pierre Chambon Submitted: December 1, 2003 **Group Art Unit** 1636 e as many sheets as necessary) **Examiner Name** Celine X. Qian Sheetrad of Attorney Docket Number 065691-0222

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CO	A11	INDRA A. et al., Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases, Nucleic Acids Research, Nov. 15, 1999, pp. 4324-4327, Vol. 27, No. 22, Oxford University Press, Surrey, GB			
	A12	VASIOUKHIN V. et al., The magical touch: Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin, Proceedings of the National Academy of Sciences of USA, July 20, 1999, pp. 8551-8556, Vol. 98, No. 15			
	A13	RAGHAVAN S. et al., Conditional ablation of betal integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination, The Journal of Cell Biology, Sept. 4, 2000, pp. 1149-1160, Vol. 150, No. 5			
	A14	FENG X. et al., Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids, Genes & Development, 1997, pp. 59-71, Vol. 11, No. 1			
	A15	SALTOU M. et al., Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor, Nature, March 9, 1995, pp. 159-162, Vol. 374, MacMillan Journals Ltd., London, GB			
	A16	LI M. et al., Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis, Nature, Oct. 5, 2000, pp. 633-636, Vol. 407, No. 6804,	_		
	A17	KASTNER P. et al., Vitamin A deficiency and mutations of RXRalpha, RXRbeta and RARalpha lead to early differentiation of embryonic ventricular cardiomyocytes, Development, Dec. 1997, pp. 4749–4758, Vol. 124, No. 23			
	A18	SUMI-ICHINOSE C. et al., SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells, Mol. Cell Biol., Oct. 1997, pp. 5976-5986, Vol. 17, No. 10			
		FEIL R. et al., Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochemical and Biophysical Research Communications, Aug. 28, 1997, pp. 752-757, Vol. 237, No. 3			
		METZGER D. et al., Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase, Proceedings of the National Academy of Sciences of USA, July 18, 1995, pp. 6991-6995, Vol. 92, No. 15, National Academy of Science, Washington, USA			
	A21	METZGER D. et al., Engineering the mouse genome by site-specific recombination, Current Opinion in Biotechnology, Oct. 1999, pp. 470-476, Vol. 10, No. 5, London, GB			
1		BARLOW C. et al., Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments, Nucleic Acids Research, 1997, pp. 2543-2545, Vol. 25, No. 12			

Examiner		Date	
Signature	1 CC	Considered	6/11/04
*EYAMMED	In the state of th		

al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
Standard ST.3) for Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
Standard ST.3) for Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document.
Standard ST.3) for Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document.
Standard ST.3) for Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document.
Standard ST.3) for Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document.
Standard ST.3) for Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document.

Standard ST.3) for Japanese patent documents are indicated as the patent document under WIPO Standard ST. 18 if possible. English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450,

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE number of information unless it contains a valid OMB control

	The state of the s	DIVID CONTINU
	Complete if Known	
Application Number	09/853.033	<u> </u>
Filing Date		
First Named Inventor		
Group Art Unit	1636	
Examiner Name	Celine X. Qian	
Attorney Docket Number	065691-0222	
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	Complete if Known Application Number 09/853,033 Filing Date 05/11/2001 First Named Inventor Pierre Chambon Group Art Unit 1636 Examiner Name Celine X. Qian

			NON PATENT LITERATURE DOCUMENTS			
	Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	To		
	cq	A23	IMAI T. et al., Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes, Proceedings of the National Academy of Sciences of USA, Jan. 2, 2001, pp. 224-228, Vol. 98, No. 1, USA			
•		A24	IMAI T. et al., Inducible site-specific somatic mutagenesis in mouse hepatocytes, Genesis, Feb. 2000, pp. 147-148, No. 2, Wiley-Liss, New York, NY, US			
		A25	WAN Y. et al., Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver, Mol. Cell Biol., June 2000, pp. 4436-4444, Vol. 20, No. 12			
	ca	A26	MAHFOUDI A. et al., Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists, Proceedings of the National Academy of Sciences of the United States, 1995, pp. 4208-4210, Vol. 92, No. 10			
	·					
L						

Examiner	~~~	Date	
Signature		Considered	6/11/04
*EYAMINED		COMPIGERED	• , . , ,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.